EBV-specific T cells as therapy for relapsed - refractory EBV-positive lymphomas

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/552469

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The presence of Epstein-Barr virus (EBV) withiin EBV-positive malignant lymphoma cases provides a potential target for adoptive immunotherapy. Previous studies have established that adoptive immunotherapy for certain subtypes of lymphoma with EBV-specific killer T cells can lead to remission of disease. The objective of this study is to examine whether a similar strategy but using an enhanced methodology can be applied for the treatment of a range of relapsed-refractory EBV-positive lymphomas.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2011

Funding Scheme: NHMRC Project Grants

Funding Amount: $324,397.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Diagnostic radiography

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Adoptive Immunotherapy | Cancer | Epstein-Barr Virus | Haematology | Hodgkins Lymphoma | Lymphoma | Non Hodgkins Lymphoma | Post Transplant Lymphoproliferative Syndrome

Related Links